Skip to main content

Table 3 Summary of included reviews that investigated modifiable factors

From: Pragmatic methods for reviewing exceptionally large bodies of evidence: systematic mapping review and overview of systematic reviews using lung cancer survival as an exemplar

Author, year

REV ID

Country

Search year*

DB

RM

CH

QA

Synthesis

PR theme

No. PFs evaluated**

LC type

No. of studies

Sample size range

Included UVA or MVA

Aboshi, 2014

182

Japan

2012

N

N

Y

N

MR

2, 4

13

NSCLC (late)

65

NS

NS

Ashworth, 2013

237

UK

2012

Y

Y

P

N

Narrative

1, 2

Any (total NS)

NSCLC (oligometastatic)

49 (23 in analysis of PFs)

NS (1064 in analysis of PFs)

MVA

Ashworth, 2014

105

UK

2012

Y

Y

Y

N

MR

1, 2, 3

20

NSCLC (oligometastatic)

20

6–262

Both

Behera, 2016

5815

US

2015

Y

N

Y

N

MA

2

2

NSCLC (I)

19 (11 survival)

8–110

NS

Berghmans, 2011

8434

Belgium

2009

N

N

P

N

Narrative

2

Any (> 50)

NSCLC (III)

39

42–2048

MVA

Brundage, 2002

1051

Canada

2001

N

N

N

N

Narrative

2

Any (169)

NSCLC

887

31–1281

MVA

Buttigliero, 2011

494

Italy

2007

Y

Y

Y

Y

Narrative

2

2

mxdC (LC/NSCLC)

25 (2 LC)

294–447

MVA

Carter, 2014

5362

US

2010

Y

P

N

Y

Narrative

2, 4

12

NSCLC (III–IV)

54

NS

MVA

Christopoulos, 2013

5789

Greece

2013

Y

Y

N

N

Narrative

2

1

LC

17

4–56 (NS for 3 studies)

NS

Deghaidy, 2005

923

Egypt

2004

N

Y

N

N

MA

2

1

LC (NSCLC/SCLC)

29

23–1342

NS

Florou, 2014

51

Greece

2013

Y

N

Y

N

Narrative

2, 4

1

mxdC NSCLC (early)/SCLC (limited)

20 (13 LC; 4 survival only)

66–2258

NS

Montazeri, 2009

703

Iran

2008

Y

N

Y

N

Narrative

2

1

mxdC NSCLC/SCLC

104 (26 LC)

30–651

MVA

Neal, 2015

8441

UK

2013

Y

Y

Y

Y

Narrative

2

15

mxdC (LC/NSCLC)

209 (20 LC)

103–566

NS

Olsson, 2009

722

US

2007

Y

Y

Y

Y

Narrative

2

1

LC

18

NS (2 studies with > 1000 pts)

Both

Parsons, 2010

695

UK

2008

Y

Y

Y

Y

MA

1, 2

1

LC (NSCLC/SCLC)

10

61–611

Both

Prades, 2015

5807

Spain

2012

N

Y

Y

N

Narrative

2

1

mxdC LC (LC/NSCLC)

51 (3 LC; 1 survival)

NS

NS

Salah, 2012

467

Jordan

2010 (IS)

Y

U

Y

N

MR

2

8

NSCLC (isolated met)

51

NS (total 62)

Both

Slatore, 2010

621

US

2008

Y

P

Y

Y

Narrative

2

1

LC (LC/NSCLC)

23 (9 survival)

249–693,697

Both

von Meyenfeldt, 2012

414

Netherlands

2011

Y

Y

P

N

MR

2

3

LC

19

987–90,088

MVA

Yu, 2015

5489

China

2014

Y

U

N

Y

MA

2

1

NSCLC

10

21–412

Yes

  1. *Where the search dates were not reported, this was based on the latest publication year of included studies (IS)
  2. **Three reviews, which evaluated ‘any’ prognostic factor included a minimum of 50 factors: Ashworth, 2013 (237); Berghmans, 2011 (8434); and Brundage, 2002 (1051)
  3. REV ID review unique identification number, DB searched more than one reference database searched, No. number, RM used explicit and reproducible methodology used, CH a systematic presentation of the characteristics of included studies presented, QA assessment for the validity of the findings of the included studies conducted, ADC adenocarcinoma, CTX chemotherapy, IS included studies, LC lung cancer, MA meta-analysis, met metastasis, MR meta-regression, MVA multivariate analysis, mxdC mixed cancer, NS not stated, N no, NSCLC non-small cell lung cancer, PF prognostic factor, PR prognostic research, RT radiotherapy, SCC squamous cell carcinoma, SCLC small cell lung cancer, surR surgical resection, sync synchronous, UVA univariate analysis, Y yes
Back to article page

Systematic Reviews

ISSN: 2046-4053